č. 2/2013 - Alergologie, pneumologie

ACTA MEDICINAE 2/2013 Kompletní literatura
ALERGOLOGIE, PNEUMOLOGIE
2
Alergologie a klinická imunologie v roce 2013
2
Patogeneze chronické obstrukční plicní nemoci a možnosti protizánětlivé léčby
3
Atopický ekzém – co nového v léčbě?
3
Kontaktní ekzém – kontaktní alergeny
4
Léčba atopické dermatitidy v přehledu
4
Role vitaminu D u chronických zánětlivých onemocnění
4
Doporučené postupy v léčbě astmatu bronchiale
5
Rinosinusitidy: od praktického lékaře do specializované péče ORL nebo alergologie?
5
Využití salinických roztoků v léčbě onemocnění horních cest dýchacích
5
Kardiovaskulární bezpečnost indakaterolu v léčbě chronické obstrukční plicní nemoci
6
Novinky v léčbě karcinomu plic
7
Chronická obstrukční plicní nemoc
7
Flutikazon furoát v léčbě alergické rýmy
7
Léčba pacienta IFN-β-1b (Betaferonem)
7
Využití certolizumab pegolu v léčbě aktivní revmatoidní artritidy
8
Účinná léčba abataceptem v první linii u pacientky s diabetem mellitem I. typu
a s revmatoidní artritidou
8
Subkutánní interferon beta-1a v léčbě roztroušené sklerózy
8
Systémová léčba osteolýzy indukované nádorem
9
Antitrombotická léčba – léčba apixabanem
9
Novinky ve fekální bakterioterapii
prof. MUDr. Václav Špičák, CSc. Immuno-flow, s. r. o., Praha, Česká iniciativa pro astma, o. p. s.
MUDr. Jan Chlumský, Ph.D. Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha
Prim. MUDr. Štěpánka Čapková Dermatologické oddělení pro děti, FN Motol, Praha
RNDr. Dana Nováková Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol, Praha
doc. MUDr. Eliška Dastychová, CSc. I. dermatovenerologická klinika LF MU a FN u sv. Anny v Brně
MUDr. Radek Litvik Kožní oddělení FN Ostrava
MUDr. Jana Čepová, Ph.D., MBA | MUDr. Margareta Beyerová | Ing. Eva Klapková, Ph.D. | Ing. Marta Pechová |
prof. MUDr. Richard Průša, CSc. Ústav lékařské chemie a klinické biochemie, 2. LF UK a FN v Motole, Praha
MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha
MUDr. Jan Pokorný, CSc. DG Centrum Ostrava, ORL
MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha
Prim. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie Nemocnice Na Bulovce a 3. LF UK Praha
prof. MUDr. Jana Skřičková, CSc. | MUDr. Marcela Tomíšková | MUDr. Bohdan Kadlec | MUDr. Lenka Jakubíková, Ph.D. |
MUDr. Jana Špaldová Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz LF a PF MU Brno
MUDr. Lucie Cwiková Městská nemocnice Ostrava-Fifejdy
MUDr. Ester Seberová RESPIRAL, s. r. o., Plzeň
MUDr. Magdaléna Hladíková, Ph.D. Neurologická klinika LF MU a FN Brno
MUDr. David Suchý, PhD. Oddělení klinické farmakologie FN Plzeň
MUDr. Petr Kopsa Revmatologické a rehabilitační oddělení Thomayerovy nemocnice, Praha
MUDr. Iva Okáčová | doc. MUDr. Pavel Štourač, Ph.D. Neurologická klinika LF MU a FN Brno, CEITEC – Středoevropský
technologický institut MU Brno
MUDr. Simona Paulíková | prof. MUDr. Jiří Petera Ph.D. | MUDr. Adam Paulík
LF UK a Klinika onkologie a radioterapie FN Hradec Králové
MUDr. Hynek Poul Oddělení hematologie a transfuziologie Nemocnice Pelhřimov, p. o.
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha
Alergologie a klinická imunologie v roce 2013
prof. MUDr. Václav Špičák, CSc. Immuno-flow, s. r. o., Praha, Česká iniciativa pro astma, o. p. s.
1 Blahoš, J. – Ticháček, B.: STOROČENKA, historie České lékařské společnosti J. E. Purkyně, ČLS JEP, 2005.
2 Špičák, V.: Genetika alergie. In: Petrů, V.: Dětská alergologie, Mladá fronta, 2012, s. 35.
3 Špičák, V.: Etiopatogeneze alergie. In: Petrů, V.: Dětská alergologie, Mladá fronta, 2012, s. 66.
4 Bochner, B. B., et al.: Advances in mechanisms of allergy and clinical
imunology in 2012. J Allergy Clin Immunol, 2013, v tisku.
5 Kauffmann, F. – Demenais, F.: Gene-environment interactions in
­asthma and allergic diseases: Challenges and perspectives. JACI, 2012,
130, s. 1229–1240.
6 Yang, I. V. – Schwarz, D. A.: Epigenetic mechanisms and the
develop­­­ment of asthma. JACI, 2012, 130, s. 1243–1255.
7 Choy, D. F., et al.: Gene expression patterns of Th2 inflammation and
intercellular communication in asthmatic airways. The Journal of Immunology, 2011, 186, s. 1861–1869.
8 Woodruff, P. C., et al.: T-helper type 2-driven inflammation defines
major subphenotypes of asthma. American J of Respiratory and Critical Care Medicine, 2009, 180, s. 388–395.
9 Von Gunten, S., et al.: Update in clinical allergy and immunology. Allergy, 2012, 67, s. 1491–1500.
10Soyer, O. U., et al.: Mechanisms of peripheral tolerance to allergens.
Allergy, 2013, 68, s. 161–170.
11Špičák, V.: České stopy v alergologii. Alergie, 2012, 14, s. 246–250.
Patogeneze chronické obstrukční plicní nemoci a možnosti
protizánětlivé léčby
MUDr. Jan Chlumský, Ph.D. Pneumologická klinika 1. LF UK, Thomayerova nemocnice, Praha
1 Bateman, E. D. – Rabe, K. F. – Calverley, P. M. A. – Goehring, U. M. –
Brose, M. – Bredenbroker, D., et al.: Roflumilast with long-acting +
2-agonists for COPD: influence of exacerbation history. European
­Respiratory Journal, 2011, 38, s. 553–560.
2 Bourdin, A. – Burgel, P.-R. – Chanez, P. – Garcia, G. – Perez, T. – Roche,
N.: Recent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbidities. European Respiratory
Review, 2009, 18, s. 198–212.
3 Burgel, P.-R. – Bourdin, A. – Chanez, P. – Chabot, F. – Chaouat, A. –
Chinet, T., et al.: Update on the roles of distal airways in COPD. European Respiratory Review, 2011, 20, s. 7–22.
4 Calverley, P. – Rabe, K. – Goehring, U. – Kristiansen, S. – Fabbri, L. –
Martinez, F., et al.: Roflumilast in symptomatic chronic obstructive
pulmonary disease: two randomised clinical trials. Lancet, 2009, 374,
s. 685–694.
5 Celli, B. R. – MacNee, W. – Agusti, A. – Anzueto, A. – Berg, B. – Buist,
A. S., et al.: Standards for the diagnosis and treatment of patients with
COPD: A summary of the ATS/ERS position paper. Eur Respir J, 2004, 23,
s. 932–946.
6 Fabbri, L. – Calverley, P. – Izquierdo-Alonso, J. – Bundschuh, D. – Brose, M. – Martinez, F., et al.: Roflumilast in moderate-to-severe chronic
obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet, 2009, 374, s. 695–703.
7 Gibson, G.: Pulmonary hyperinflation a clinical overview. Eur Respir J,
1996, 9, s. 2640–2649.
8 Gibson, G.: Lung volumes and elasticity. Clin Chest Med, 2001, 22,
s. 623–635.
9 Grootendorst, D. C. – Gauw, S. A. – Verhoosel, R. M. – Sterk, P.
J. – Hospers, J. J. – Bredenbroker, D., et al.: Reduction in sputum
neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast
in patients with COPD. Torax, 2007, 62, s. 1081–1087.
10Hatzelmann, A. – Morcillo, E. – Lungarella, G. – Adnot, S. – Sanjar, S. –
Beume, R., et al.: The preclinical pharmacology of roflumilast—a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther, 2010, 23, s. 235–256.
11McIvor, R. A.: Future options for disease intervention: Important
advances in phosphodiesterase 4 inhibitors. European Respiratory Review, 2007, 16, s. 105–112.
12O‘Donnell, D. – Laveneziana, P.: Physiology and consequences of lung
hyperinflation in COPD. Eur Respir Rev, 2006, 15, s. 61–67.
13O‘Donnell, D. – Laveneziana, P.: The clinical importance of dynamic
lung hyperinflation in COPD. COPD, 2006, 3, s. 219–232.
14O‘Donnell, D. – Webb, K.: Exertional breathlessness in patients with
chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis, 1993, 148, s. 1351–1357.
15O´Donnell, D. E. – Bredenbroker, D. – Brose, M. – Webb, K. A.: Phy­sio­­­
logical effects of roflumilast at rest and during exercise in COPD. European Respiratory Journal, 2012, 39, s. 1104–1112.
16Rabe, K.: Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev Resp Med, 2010, 4, s. 543–555.
17Rabe, K. – Hurd, S. – Anzueto, A. – Barnes, P. – Buist, S. – Calverley,
P., et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 2007, 176, s. 532–555.
18Suissa, S. – Barnes, P.: Inhaled corticosteroids in COPD: the case
­against. Eur Respir J, 2009, 34, s. 13–16.
19White, W. B., et al.: ATS 2011, P E71.
20Wouters, E. F. M., et al.: J Clin Endocrinol Metab, 2012, 97 (9), s. E1720–
–E1725.
ACTA MEDICINAE 2/2013 ALERGOLOGIE, PNEUMOLOGIE Kompletní literatura
Atopický ekzém – co nového v léčbě?
Prim. MUDr. Štěpánka Čapková Dermatologické oddělení pro děti, FN Motol, Praha
RNDr. Dana Nováková Klinika nukleární medicíny a endokrinologie UK 2. LF a FN Motol, Praha
1 Paller, A. S. – Mancini, A. J.: Hurwitz clinical pediatric dermatology.
Fourth edition multimedia on line. Elsevier Saunders, 2011, s. 624.
2 Bieber, T. – Cork, M. – Reitamo, S.: Atopic dermatitis: a candidate for
disease-modifying strategy. Allergy, 2012, 67, s. 969–975.
3 Benáková, N.: Atopická dermatitida v roce 2009. Čes-slov Derm, 2009,
84, s. 65–86.
4 Baron, S. E. – Cohen, S. N. – Archer, C. B.: Guidance on the diagnosis
and clinical management of atopic eczema. Clinical and Experimental
Dermatology, 2012, 37, s. 7–12.
5 Akdis, C. A. – Akdis, M. – Bierber, T., et al.: Diagnosis and treatment
of atopic dermatitis in children and adults: European Academy of Allergology and Clinilcal Imunology / American Academy of Allergy,
6
7
8
9
­ sthma and Immunology / PRACTALL Consensus Report. J Allergy Clin
A
Immunol, 2006, 118, s. 152–169.
Ring, J. – Alomar, A. – Bieber, T., et al.: Guidelines for treatment of atopic eczema (atopic dermatitis) Part I. JEADV, 2012, 26, s.1045–1060.
Ring, J. – Alomar, A. – Bieber, T., et al.: Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. JEADV, 2012, 26, s. 1176–1193.
Hoare, C. – Li Wan Po, A. – Wiliams, H.: Systematic review of tretments
for atopic eczema. Health Technol Assess, 2000.
Darsow, U. – Wollenberg, A. – Simon, D., et al.: ETFAD/EADV eczema
task force 2009 position paper on diagnosis and treatment of atopic
dermatitis. JEADV, 2010, 24, s. 317–328.
Kontaktní ekzém – kontaktní alergeny
doc. MUDr. Eliška Dastychová, CSc. I. dermatovenerologická klinika LF MU a FN u sv. Anny v Brně
1 Beckmann, B. – Ippen, H.: Teebaum-Öl. Dermatose, 1998, 46,
s. 120–124.
2 Camarasa, J. G.: Contact dermatitis to ketoprofen. Contact Dermatitis,
1985, 12, s. 120–122.
3 Cavelier, C. – Foussereau J.: Kontaktalergie gegen Metalle und deren
Slze. Teil II. Nickel, Kobalt, Quecksilber und Palladium. Dermatosen in
Beruf und Umwelt, 1995, 43, s. 152–162.
4 Coz, Ch. J. L. – Bottlaender, A. – Scrivener, J. N. – Santinelli, F. – Cribier, B. J. – Heid, E. – Grosshans, E. M.: Photocontact dermatitis from
ketoprofen and tiaprofenic acid: Cross-reactivity sutdy in 12 consecutive patients. Contact Dermatitis, 1998, 38, s. 245–252.
5 Dastychová, E.: Nežádoucí účinky extern obsahujících ketoprofen. Čs
Derm, 2000, 75, s. 51–55.
6 Dooms-Goossens, A. – Andersen, K. E. – Brandao, F. M. – Bruyn­zeel,
D. – Burrows, D. – Camarasa, J. – Ducombs, G. – Frosch, P. – Hannuksela, M. – Lachapelle, J. M. – Lathi, A. – Menné, A. – Wahlberg, J.
E. – Wilkinson, J. D.: Corticosteroid contact allergy: an EECDRG multicentre study. Contact Dermatitis, 1996, 35, s. 40–44.
7 Foussereau, J.: An epidemiological study of contact allergy to 5-chloro-3-methylisothiazolone 3-methyl-isothiazolone in Strasbourg. Contact Dermatitis, 1990, 22, s. 68–70.
8 Gebhardt, M. – Wollina, U.: Kutane Nebenwirkungen nichtsteroidaler Antiflogistika. Z Rheumatol, 1995, 54, s. 405–412.
9 Greig, J. E. – Thoo, S. L. – Carson, Ch. F. – Riley, T. V.: Allergic contact
dermatitis following use of a tea tree oil hand-wash not due to tea
tree oil. Contact Dermatitis, 1999, 41, s. 354.
10Groot, A. C.: Airborne allergic contact dermatitis from Tea Tree Oil. Contact Dermatitis, 1996, 35, s. 304–305.
11Groot, A. C. – Frosch, P. J.: Averse reactions to fragrances. A clinical review. Contact Dermatitis, 1997, 36, s. 57–86.
12Kränke B.: Allergisierende Potenz von Teebaum-Öl. Hautarzt, 1997, 48,
s. 203–204.
13Lehmann, P. – Werner, A. – Bäuerle, G. – Breit, R. – Frosch, P. –
Fuchs, T. – Günter, G. – Neumann, N. J. – Schaller, J. – Schulze-Dirks,
A. – Vieluf, D. – Wilhelm, P.: Coricosteroid contact dermatitis: Result
of a multicenter study from the German Contact Allergy Group. Dermatosen, 1997, 45, s. 116–120.
14Mozzanica, N. – Pigatto, P. D.: Contact and photocontact allergy to
ketoprofen: Clinical and experimental study. Contact Dermatitis, 1990,
23, s. 336–340.
15Rietschel, R. L. – Fowler, J. F., jr.: Fischer’s Contact dermatitis, 2008,
s. 275–278, 287–288, 670–681, 393–404.
16Semrádová, V. – Dastychová, E. – Navrátilová, Z.: Kontaktní alergie
na kortikosteroidy. Čs Derm, 1999, 74, s. 113–117.
17Semrádová, V. – Dastychová, E.: Polyvalent contact allergy to corticosteroids: A report of two cases. JEADV, 2001, 15, s. 350–353.
18Urbanček, S.: Alergény štandardnej série. In: Urbanček, S. – Dastychová, E. – Buchvald, D. – Vocilková, A.: Kontaktné alergény v pracovnom
a životnom prostredí, 2006, s. 41–73.
19Uter, W. – Lessmann, H. – Geier, J. – Schnuch, A.: Contact allergy to
ingredients of hair cosmetics in female hairdressers and clients — an
8-year analysis of IVDK data. Contact Dermatitis, 2003, 49, s. 236–240.
20Uter, W. – Hegewald, J. – Aberer, W. – Ayala, F. – Bircher, A. J. – Brach,
J. – Coenraads, P.-J. – Schuttellar, M.-L. A. – Elsner, P. – Fartasch, M. –
Mahler, V. – Fortina, A. B. – Frosch, P. J. – Fusch, T. – Johansen, J. D. –
Menné, T. – Jolanou, R. – Krêcisz, B. – Kiec-Swierczynka, M. – Larese, F. – Orton, D. – Peserico, A. – Rantanen, T. – Schnuch, A.: The European standard series in 9 European countries, 2002/2003 — First results of the European Surveillance Systém on Contact Allergies. Contact dermatitis, 2005, 53, s. 136–145.
21Wilkinson, S. M.: Hypersensitivity to topical corticosteroids. Clin Exp
Derm, 1994, 19, s. 1–11.
22Wilkinson, S. M. – Hollis, S. – Beck, M. H.: Reaktionen auf andere Kortikosteroide bei Patienten mit allergischer Kontaktdermatitis infolge
Hydrocortison. Z Hautkr, 1995, 70, s. 368–372.
23The ESSCA Writing Group: The European Surveillance System of Contact Alleries (ESSCA): results of patch rating the standard series, 2004.
JEADV, 2008, 22, s. 174–181.
ACTA MEDICINAE 2/2013 ALERGOLOGIE, PNEUMOLOGIE Kompletní literatura
Léčba atopické dermatitidy v přehledu
MUDr. Radek Litvik Kožní oddělení FN Ostrava
1 Litvik, R.: Atopický ekzém dospělého věku. In: Dermatologie v kazuistikách. Praha, Mladá fronta, 2008, s. 187–194.
2 Litvik, R.: Úloha kožní bariéry u atopické dermatitidy. Farmakoterapie,
2008, s. 11–21.
3 Proksch, E.: The role of emollients in the management of diseases with
chronic dry skin. Skin Pharmacol Physiol, 2008, 21, s. 75–80.
4 Meibach, H. I. – Surber, Ch.: Topical Corticosteroids. Basel, Karger, 1992.
5 Litvik, R.: Tacrolimus v koncentraci 0,03 % a 0,1 % ve formě masti. Farmakoterapie, 2008, s. 5–10.
6 Simpson, E. L. – Hanifin, J. M.: Atopic dermatitis. J Am Acad Dermatol,
2005, 53, s. 115–128.
7 Hanifin, J. M. – Cooper, K. D., et al.: Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines“. J Am Acad Dermatol, 2004, 50, s. 391–404.
8 Jung, T. – Stingl, G.: Atopic dermatitis: therapeutic concepts evolving
from new pathophysiologic insights. J Allergy Clin Immunol, 2008, 122,
s. 1074–1081.
9 Benáková, N.: Atopická dermatitida. In: Léčba atopické dermatitidy v novém milleniu. Praha, Astellas Pharma, 2005, s. 3–6.
10Polášková, S.: Proč může selhat léčba u dětí s atopickou dermatitidou.
Farmakoterapie, 2008, s. 32–35.
11Barbaud, A., et al.: Interest in an emollient containing pentyl rhamnoside in the management of xerosis and atopic skin. Cosmetic Dermatology, 2008, 21, s. 647–651.
12Cork, M. J., et al.: J Allergy Clin Immunol, 2006, 118, s. 3–21.
13Leung, D. Y. M. – Soter, N. A.: J Am Acad Dermatol, 2001, 44 (dopl.),
s. S1–12.
14Cork, M., et al.: Dermatology Update. Montreal, Kanada, 6.–7. 11. 2003.
15ISAAC Steering Committee: Lancet, 1998, 351, s. 1225–1232.
16Bieber, T.: N Engl J Med, 2008, 358, s. 1483–1494.
17Beattie, P. E. – Lewis-Jones, M. S.: Br J Dermatol, 2006, 155, s. 145–151.
18Spergel, J. M.: Am J Clin Dermatol, 2008, 9, s. 233–244.
19Cork, M. J., et al.: Epidermal barrier dysfunction in atopic dermatitis.
In: Rawlings, A. V. – Leyden, J. J. (eds.): Skin Moisturization. London, Informa Healthcare, 2009 (v tisku).
Role vitaminu D u chronických zánětlivých onemocnění
MUDr. Jana Čepová, Ph.D., MBA | MUDr. Margareta Beyerová |
Ing. Eva Klapková, Ph.D. | Ing. Marta Pechová | prof. MUDr. Richard Průša, CSc.
Ústav lékařské chemie a klinické biochemie, 2. LF UK a FN v Motole, Praha
1 Nevoral, J.: Cílený screening celiakie. Postgraduální medicína, 2010, 76,
s. 452.
2 Kohout, P.: Celiakie. Postgraduální medicína, 2010, 82, s. 463–477.
3 Novotná, B.: Vitamin D – imunita, alergie a astma. Medical Tribune,
2012, 5.
4 Krejsek, J. – Kopecký, O.: Klinická imunologie. NUCLEUS HK, 2004.
5 Holick, M. F.: The Vitamin D solution. Hudson Street Press, USA, 2011.
6 Holick, M. F.: Vitamin D Deficiency. New Engl J Med, 2007, 357,
s. 266–281.
7 IOF Releases New Position Statement on Vitamin D ­Reccommendations
for Older Adults, Florencie, 2010, www.nutritionhorizon.com.
8 Čepová, J. – Kolářová, J. – Pechová, M. – Kotaška, K. – Průša, R.: Kazuistiky
z osteologické ambulance. Interní medicína pro praxi, 2012, 14, 2, s. 78–80.
9 Čepová, J. – Pechová, M. – Beyerová, M.: Kazuistiky z osteologické
ambulance. Farmakoterapie – klinická praxe, 2012, 8.
10Brouwer-Brolsma, E. M. – Bischoff-Ferrari, H. A., et al.: Vitamin D: do
we get enough? Osteoporosis Int, 2012, s00198-012-2231-3.
11Palička, V.: Vitamin D a jeho role (nejen) v osteologii. Interní medicína
pro praxi, 2011, 13 (10), s. 383–387.
12Raška, I.: Vitamin D v prevenci onemocnění? Medicína po promoci,
2012, 4.
13Kvapil, M.: Diabetologie 2012. Triton, 2012.
14Čepová, J.: Vitamin D ve zdraví a nemoci, 13. Bergmeyerova konference. Labor Aktuell, 2012, 2.
Doporučené postupy v léčbě astmatu bronchiale
MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha
1 Global Initiative for Astma (GINA). GINA workshop report: Global strategy for astma management and prevention. http://www.ginasthma.com.
2 Banks, E. D. – Jalloul, A.: Occupational astma, work-related astma and
reactive airways dysfunction syndrome. Curr Opin Pulm Med, 2007, 13,
s. 131–136.
3 Wenzel, S. E. – Covar, R.: Update in astma 2005. Am J Respir Crit Care
Med, 2006, 173, s. 698–706.
4 Turner, S.: Exhaled nitric oxide in the diagnosis and management of
astma. Curr Opin Allergy Clin Immunol, 2008, 8, s. 70–76.
5 Michils, A. – Baldassarre, S. – Van Muylem, A.: Exhaled nitric oxide
and astma kontrol: A longidutinal study in unselected patiens. Eur Respir J, 2008, 31, s. 539–546.
6 Sutherland, E. R. – Martin, R. J.: Astma and Atypical Bacterial Infec­
tion. Chest, 2007, 132, s. 1962–1966.
7 Moore, W. C. – Peters, S. P.: Update in Astma 2006. Am J Respir Crit Care
Med, 2007, 175, s. 649–654.
8 Tamesis, G. P. – Krawiec, M. E.: Heterogenity in response to astma medications. Curr Opin Allergy Clin Immunol, 2007, 7, s. 185–189.
9 Holgate, S. – Casale, T. – Wenzel, S. – Bousquet, J. – Deniz, Y. – Reisner, C.: The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol, 2005,
115, s. 459–465.
11Aubier, M. – Buhl, R. – Ekstrom, T. – Ostinelli, J. – van Schayck, C.P. –
Selroos, O. – Haughney, J.: Comparison of two twice-daily doses of
ACTA MEDICINAE 2/2013 ALERGOLOGIE, PNEUMOLOGIE Kompletní literatura
budesonide/formoterol maintance and reliever therapy. Eur Repir J,
2010, 36, s. 524–530.
11Kašák, V.: Kontrola astmatu a exacerbací. Medicína po promoci, 2010,
11, s. 69–73.
12Ekerljung, L. – Bossios, A. – Lotvall, J. – Olin, A. C. – Ronmark, E.: Multi-symptom asthma as an indication of disease severity in epidemiology. Eur Repir J, 2011, 38, s. 825–832.
13Pauk, N.: Současný pohled na postavení LABA v terapii astmatu. Farmakoterapie, 2010, 6, s. 449–452.
Rinosinusitidy: od praktického lékaře do specializované péče
ORL nebo alergologie?
MUDr. Jan Pokorný, CSc. DG Centrum Ostrava, ORL
1 Markalous, B. – Charvát, F., et al.: Zobrazení hlavy. Triton, 2006, 658 s.
2 Kuchynková, Z.: Nosní polypy. Galén, 2003, 100 s.
Využití salinických roztoků v léčbě onemocnění horních
cest dýchacích
MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha
1 Middleton, P. G. – Pollard, K. A. – Wheatley, J. R.: Hypertonic saline
alters ion transport across the human airway epithelium. Eur Respir J,
2001, 17, s. 195–199.
2 Talbot, A. R. – Herr, T. M. – Parsons, D. S.: Mucociliary clearance
and buffered hypertonic saline solution. Laryngoscope, 1997, 107,
s. 500–503.
3 Greiff, L. – Andersson, M. – Wollmer, P. – Persson, C. G.: Hypertonic
saline increases secretory and exudative responsiveness of human nasal airway in vivo. Eur Respir J, 2003, 21, s. 308–312.
4 Kim, C. H. – Hyun, S. M. – Eun, A. Y. – Lee, J. G. – Yoon, J. H.: Effect of
hypo-, iso- and hypertonic saline irrigation on secretory mucins and
morphology of cultured human nasal epithelial cells. Acta Otolaryngol, 2005, 125, s. 1296–1300.
5 Kim, J. Y. – Hong, Y. S. – Choi, S. H. – Yoon, Y. H. – Moon, S. W. – Lee,
S. W.: Effect of hypertonic saline on apoptosis of polymorphonuclear
cells. J Surg Res, 2012, 178, s. 401–408.
6 Han, C. – Choi, S. H. – Yoon, Y. H., et al.: Hypertonic saline downregulate the production level of lipopolysaccharide-induced migration inhibitory factor in THP-1 cells. J Korean Surg Soc, 2012, 82, s. 1–7.
7 Garavello, W. – Romagnoli, M. – Sordo, L. – Gaini, R. M. – Di Berardino, C. – Angrisano, A.: Hypersaline nasal irrigation in children with
symptomatic seasonal allergic rhinitis: A randomized study. Pediatr Allergy Immunol, 2003, 14, s. 140–143.
8 Garavello, W. – Romagnoli, M. – Gaini, R. M.: Hypertonic or isotonic
saline for allergic rhinitis in children. Pediatr Allergy Immunol, 2005, 16,
s. 91–92.
9 Shoseyov, D. – Bibi, H. – Shai, P. – Shoseyov, N. – Shazberg, G. – Hurvitz, H.: Treatment with hypertonic saline versus normal saline nasal
wash of pediatric chronic sinusitis. J Allergy Clin Immunol, 1998, 101,
s. 602–605.
10Taccariello, M. – Parikh, A. – Darby, Y. – Scadding, G.: Nasal douching
as a valuable adjunct in the management of chronic rhinosinusitis. Rhinology, 1999, 37, s. 29–32.
11Rabago, D. – Pasic, T. – Zgierska, A. – Mundt, M. – Barrett, B. – Maberry, R.: The efficacy of hypertonic saline nasal irrigation for chronic
sinonasal symptoms. Otolaryngol Head Neck Surg, 2005, 133, s. 3–8.
12Adappa, N. D. – Wei, C. C. – Palmer, J. N.: Nasal irrigation with or with­
out drugs: the evidence. Curr Opin Otolaryngol Head Neck Surg, 2012,
20, s. 53–57.
13Harvey, R. – Hannan, S. A. – Badia, L. – Scadding, G.: Nasal saline irrigations for the symptoms of chronic rhinosinusitis. Cochrane Database Syst Rev, 2007, CD006394.
14Friedman, M. – Hamilton, C. – Samuelson, C. G., et al.: Dead Sea salt
irrigations vs saline irrigations with nasal steroids for symptomatic
treatment of chronic rhinosinusitis: A randomized, prospective double-blind study. Int Forum Allergy Rhinol, 2012, 2, s. 252–257.
15Rabago, D. – Zgierska, A.: Saline nasal irrigation for upper respiratory conditions. Am Fam Physician, 2009, 80, s. 1117–1119.
Kardiovaskulární bezpečnost indakaterolu v léčbě chronické
obstrukční plicní nemoci
Prim. MUDr. Norbert Pauk, Ph.D. Klinika pneumologie Nemocnice Na Bulovce a 3. LF UK Praha
1 Kašák, V.: Indacaterol – první inhalační β2-agonista s ultradlouhodobým účinkem (ultra-LABA) pro léčbu CHOPN. Farmakoterapie, 2010,
6, 1, s. 40–49.
2 Zindr, V.: Bezpečnost indakaterolu v ročních studiích. Stud Pneumol
Phtiseol, 2011, 71 (4), s. 171–178.
3 Khnidri, S. – Sabo, R. – Hartus, S. –Jennings, S. – Drollmann, A. F.:
A thorough QT study on the effect of indacaterol on cardiac safety in
healthy subjects. Am J Respir Crit Care Med, 2009, 179, A2463.
4 Chapman, K. R. – Rennard, S. I. – Dogra, A. – Owen, R. – Larsen, C. –
Kamer, B.: Long-term safety and efficacy of indacaterol, a novel long-acting beta2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest, 2011, 140 (1), s. 68–75.
5 Dahl, R. – Chung, K. F. – Buhl, R., et al.: Efficacy of a new once-daily
long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax, 2010, 65, s. 473–479.
7 Buhl, R. – Dunn, L. J. – Disdier, C. – Larsen, C. – Amos, C. – Henley,
ACTA MEDICINAE 2/2013 ALERGOLOGIE, PNEUMOLOGIE Kompletní literatura
M. – Kamer, B.: Eur Respir J, 201, 38, s. 797–803.
8 Donohue, J. F. – Fogarty, C. – Lotvall, J., et al.: Once-daily bronchodilators for chronic obstructive pulmonary disease disease: indacaterol versus tiotropium. Am J Respir Crit Care Med, 2010, 182, s. 155–162.
9 Worth, H. – Chung, K. F. – Felser, J. M. – Hu, H. – Rueegg, P.: Car­
dio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respiratory Medicine, 2011, 105,
s. 571–579.
Novinky v léčbě karcinomu plic
prof. MUDr. Jana Skřičková, CSc. | MUDr. Marcela Tomíšková | MUDr. Bohdan Kadlec | MUDr. Lenka
Jakubíková, Ph.D. | MUDr. Jana Špaldová Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
doc. RNDr. Ladislav Dušek, Ph.D. Institut biostatistiky a analýz LF a PF MU Brno
1 Bonomi, P.: Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. Lung Cancer, 2003, 41, s. 43–48.
2 Cappuzzo, F. – Ciuleanu, T. – Stelmakh, L., et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol,
2010, 11, s. 521–529.
3 Ciuleanu, T. – Brodowicz, T. – Zielinski, C., et al.: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind,
phase 3 study. Lancet, 2009, 374, s. 1432–1440.
4 Duffield, E. L. – Watkins, C. L. – Armour, A. A. – Fukuoka, M.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 2009, 361, s. 947–957.
5 Giroux, D. J. – Rami-Porta, R. – Chansky, K., et al.: The IASLC Lung Cancer Staging Project: data elements for the prospective project. J Thorac Oncol, 2009, 4, s. 679–683.
6 Cheng, S. – Evans, W. K. – Stys-Norman, D. – Shepherd, F. A.: Chemotherapy for relapsed small cell lungcancer: a systematic review and
practice guideline. J Thorac Oncol, 2007, 2, s. 348–354.
7 Kim, E. S. – Hirsch, V. – Mok, T., et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer: a randomised Phase III ­trial
(INTEREST). Lancet, 2008, 372, s. 1809–1818.
8 Kwak, E. L. – Bang, Y. J. – Camidge, D. R., et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 2010,
363, s. 1693–1703.
9 Lynch, T. J. – Bell, D. W. – Sordella, R., et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350, s. 2129–2139.
10Miller, V. A. – O’Connor, P. – Soh, C., et al.: A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion
of chemotherapy with B for first-line treatment of locally advanced,
recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol, 2009, 27, s. 18.
11Murray, N. – Turrisi, A. T.: A review of first-line treatment for small-cell
lung cancer. J Thorac Oncol, 2006, 1, s. 270–278.
12National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): nonsmall cell lung cancer, verze
2. 2012 [online]. Dostupné z: www.nccn.com [vyhledáno 20. 10. 2011].
13NCCN Clinical Praktice Guidelines in Oncology: Small cell lung cancer. NCCN National Comprehensive Cancer Network, verze 1. 2008,
2007, www.nccn.org, 24–25.
14Niho, S. – Kubota, K. – Yoh, K., et al.: Clinical outcome of chemora­
dia­tion therapy in patients with limited-disease small cell lung cancer
with ipsilateral pleural effusion. J Thorac Oncol, 2008, 3, s. 723–727.
15Patel, S. – MacDonald, O. K. – Suntharalingam, M.: Evaluation of the
use of prophylactic cranial irradiation in small cell lung cancer. Cancer, 2009, 115, s. 842–850.
16Paz-Ares, L. – de Marinis, F., et al.: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for
advanced non-squamous non-small-cell lung cancer (PARAMOUNT):
a double-blind, phase 3, randomised controlled trial. Lancet Oncol,
2012, 13, s. 247–255.
17Pešek, M., et al.: Bronchogenní karcinom. Praha, Galén, 2002.
18Pešek, M. – Skřičková, J. – Kolek, V., et al.: Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. Stud
­Pneu­mol Phtiseol, 2009, 69, s. 62–68.
19Pešek, M.: Nemalobuněčný karcin plic. EUNI. http://www.euni.cz/tema.
php?
20Pijls-Johannesma, M. – De Ruysscher, D. – Vansteenkiste, J., et al.: Timing of chemoradiotherapy in patients with limited stage small-cell
lung cancer: a systematic review and meta-analysis of randomised
controlled trials. Cancer Treat Rev, 2007, 33, s. 461–473.
21 Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin
Oncol, 2009, 27, s. 1227–1234.
22Sculier, J. – Pand Moro-Sibilot, D.: First-and second-line therapy for
advanced non-small-cell lung cancer. Eur Respir J, 2009, 33, s. 915–930.
23Shaw, A. T. – Yeap, B. Y. – Solomon, B., et al.: Effect of crizotinib on
over­all survival in patients with advanced non-small-cell lung cancer
harbouring ALK gene rearrangement: a retrospective analysis. Lancet
Oncol, 2011, 12, s. 1004–1012.
24Shepherd, F. A. – Evans, W. K. – Feld, R., et al.: Adjutant chemotherapy following surgical resection for small-cell carcinoma of thelung.
J Clin Oncol, 1988, 6, s. 832–838.
25Shepherd, F. A. – Pereira, J. R. – Ciuleanu, T., et al.: Erlotinib in pre­
viously treated non-small-cell lung cancer. N Engl J Med, 2005, 353,
s. 123–132.
26Schneider, B. J.: Management of recurrent small cell lung cancer. J Natl
Compr Canc Netw, 2008, 6, s. 323–331.
27Simon, M. – Argiris, A. – Murren, J. R.: Progress in the therapy of small-cell lung cancer. Crit Rev Oncol Hematol, 2004, 49, s. 119–133.
28Skřičková, J. – Kolek, V., et al.: Základy moderní pneumoonkologie.
­Max­­dorf, Praha, 2012, s. 490.
29Soda, M. – Choi, Y. L. – Enomoto, M., et al.: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature,
2007, 448, s. 561–566.
30Soda, M. – Takada, S. – Takeuchi, K., et al.: A mouse model for
EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA, 2008, 105,
s. 19893–19897.
31Wong, D. W. – Leung, E. L. – So, K. K., et al.: The EML4-ALK fusion gene
is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer, 2009, 115, s. 1723–1733.
32Yang, J. CH. – Schuler, M. – Yamamoto, N. – O’Byrne, K. – Hirsh, V. –
Tony Mok, T., et al.: LUX-Lung 3: a randomized, open-label, Phase III
study of afatinib vs cisplatin/pemetrexed as 1st-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol, 2012, 30 (dopl.; abstrakt LBA7500).
33Zatloukal, P. – Petruželka, L.: Karcinom plic. Praha, Grada, 2001.
ACTA MEDICINAE 2/2013 ALERGOLOGIE, PNEUMOLOGIE Kompletní literatura
Chronická obstrukční plicní nemoc
MUDr. Lucie Cwiková Městská nemocnice Ostrava-Fifejdy
1 Kolek, V. – Kašák, V. – Vašáková, M.: Pneumologie. Maxdorf, 2011, s. 552.
Flutikazon furoát v léčbě alergické rýmy
MUDr. Ester Seberová RESPIRAL, s. r. o., Plzeň
1 Strachan, D. – Sibbald, B., et al.: Worldwide variation of prevalence of
symptoms of allergic rhinoconjunctivitis in children (ISAAC). ­Pediatr
Allergy Immunol, 1997, 8, s. 161–176.
2 Bousquet, et al.: ARIA 2008 Update. Allergy, 2008, 63, s. 8–160.
3 Salter, M., et al.: GW685698-enhanced afinity for glucocorticoid receptor: celular and in vivo pharmacology, prezentováno na: XXV Congres
of EAACI, Viena, 2006, abstrakt 781.
4 Salter, M., et al.: Fluticason furouat-enhanced celular and tissue protec­tion
with a new selective glucocorticoid antagonist. AAACI, Philadelphia, 2006.
5 Allen, A., et al.: Tolerability, safety and pharmacocinetics and bioavailibility of INSFF in healthy subjects. ACAAI, Philadelphia, 2006.
6 Fuad, M. – Kimberly, A., et al.: Nasal ocular reflex and eye symptoms
in patients with allergic rhinitis. Ann Allergy Asthma Immunol, 2008,
100, s. 194–199.
Léčba pacienta IFN-β-1b (Betaferonem)
MUDr. Magdaléna Hladíková, Ph.D. Neurologická klinika LF MU a FN Brno
1 Mendes, A. − Sá, M. J.: Classical immunomodulatory therapy in multiple sclerosis: How it acts, how it works. Arq Neuropsiquiatr, 2011, 69,
s. 536–543.
2 The IFN-β Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of
a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 1993, 43, s. 655–661.
3 European Study Group on Interferon β-1b in Secondary Progressive MS: Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis.
Lancet, 1998, 3523, s. 1491–1497.
4 Kappos, L. − Polman, C. H., et al.: Treatment with interferon beta-1b
delays conversion to clinically definite and McDonald MS in patients
with clinically isolated syndromes. Neurology, 2006, 67, s. 1242–1249.
5 Kappos, L. − Freedman, M. S., et al.: Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year followup analysis of the BENEFIT
study. Lancet, 2007, 370, s. 389–397.
6 Edan, G. − Kappos, L., et al.: Long-term effect of early treatment with
interferon beta-1b after a first clinical event suggestive of multiple
sclerosis: 8-year observational extension of the phase 3 BENEFIT trial.
Mult Scler, 2011, 10 (dopl.).
7 Durelli, L. − Verdun, E., et al.: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of
a 2-year prospective randomised multicentre study (INCOMIN). Lancet, 2002, 359, s. 1453–1460.
8 O‘Connor, P. − Filippi, M., et al.: 250 microg or 500 microg interferon
beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet
Neurol, 2009, 8, s. 889–897.
9 Cadavid, D. − Wolansky, L. J., et al.: Efficacy of treatment of MS with
IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology, 2009, 72, s. 1976–1983.
10Polman, C. H. − Bertolotto, A., et al.: Recommendations for clinical
use of data on neutralising antibodies to interferon-beta therapy in
multiple sclerosis. Lancet Neurol, 2010, 9, s. 740–750.
Využití certolizumab pegolu v léčbě aktivní revmatoidní artritidy
MUDr. David Suchý, PhD. Oddělení klinické farmakologie FN Plzeň
1 Venkovský, J.: Certolizumab pegol v léčbě revmatoidní artritidy. Remedia, 2009, 19, s. 308–311.
2 Zeman, J.: Certolizumab a léčba revmatoidní artritidy. Klin Farmakol
Farm, 2011, 25, s. 76–78.
3 Strojil, J. – Ciferská, H.: Certolizumab pegol. Klin Farmakol Farm, 2010,
24, s. 155–160.
4 Fleischmann, R. – Vencovsky, J. – van Vollenhoven, R. F., et al.: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in
patients with rheumatoid arthritis failing previous disease-modifying
antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis, 2009,
68, s. 805–811.
5 Keystone, E. C. – Fleischmann, R. – Smolen, J., et al.: Sustained
efficacy of certolizumab pegol added to methotrexate (MTX) in the
treatment of rheumatoid arthritis (RA): 2-year results from the RAPID
1 ­trial. Ann Rheum Dis, 2009, 68, s. 237.
6 Smolen, J. – Landewé, R. B. – Mease, P., et al.: Efficacy and safety of
certolizumab pegol plus methotrexate in active rheumatoid arthritis:
the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis, 2009,
68, s. 797–804.
7 Olejárová, M.: Bezpečnost a účinnost certolizumab pegolu v léčbě
revmatoidní artritidy. Farmakoterapie, 2011, 7, s. 335–341.
8 Mariette, X. – van Vollenhoven, R. F. – Bykerk, V. P., et al.: Safety update on certolizumab pegol in patiens with active RA with long term exposure. Arthritis Rheum, 2012, 10, s. 221.
ACTA MEDICINAE 2/2013 ALERGOLOGIE, PNEUMOLOGIE Kompletní literatura
Účinná léčba abataceptem v první linii u pacientky s diabetem
mellitem I. typu a s revmatoidní artritidou
MUDr. Petr Kopsa Revmatologické a rehabilitační oddělení Thomayerovy nemocnice, Praha
1 Schiff, M. – Bessete, L., et al.: Evaluation of abatacept in biologic-naive patients with active rheumatoid arthritis. Clin Rheumatol, 2010, 29,
s. 583–591.
2 Weinblatt, M. – Combe, B., et. al.: Safety of the selective costimula­
tion modulator abatacept in rheumatoid arthritis patients receiving
back­ground biologic and nonbiologic disease-modifying antirheumatic drugs. Arthritis & Rheumatism, 2006, 54, s. 2807–2816.
3 Schiff, M. – Keiseman, M. – Codding, C., et al.: Clinical response and
tolerability to abatacept in patients with rheumatoid arthritis pre­
viously treated with infliximab or abatacept: open-label extension of
the ATTEST Study. Ann Rheum Dis, 2011, 70, s. 2003–2007.
4 Kremer, J. M. – Russell, A. S., et al.: Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis, 2011, 70,
s. 1826–1830.
5 Orban, T. – Bundy, B., et al.: Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised,
double-blind, placebo-controlled trial. Lancet, 2011, doi: 10.1016/
S0140-6736(11)60886-6.
Subkutánní interferon beta-1a v léčbě roztroušené sklerózy
MUDr. Iva Okáčová | doc. MUDr. Pavel Štourač, Ph.D. Neurologická klinika LF MU a FN Brno,
CEITEC – Středoevropský technologický institut MU Brno
1 Havrdová, E., et al.: Roztroušená skleróza. In: Neuroimunologie. Maxdorf, 2001, s. 150–151.
2 Bednařík, J. – Amber, Z. – Růžička, E., et al.: Roztroušená skleróza. In:
Klinická neurologie, část speciální I. Triton, 2010, s. 509–510.
3 Kappos, L. – Polman, C. H. – Freedman, M. S., et al.: Treatment with
interferon b-1b delays conversion to clinically definite and McDonald
MS in patients with clinically isolated syndromes. Neurology, 2006, 67,
s. 1242–1249.
4 Štourač, P.: Imunomodulační léčba roztroušené sklerózy mozkomíšní v klinických a zobrazovacích parametrech. Cesk Slov Neurol N, 2012,
75, s. 404–410.
5 Horáková, D.: Klinicky izolovaný syndrom a prognostické markery u roztroušené sklerózy. Proč léčit včas? Neurol. pro praxi, 2008, 9,
s. 215–217.
6 Havrdová, E.: Roztroušená skleróza. Cesk a Slov Neurol Neurochir, 2008,
71, s. 121–132.
7 The IFNβ Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNβ
Multiple Sclerosis Study Group. Neurology, 1993, 43, s. 655–661.
8 Jacobs, L. D. – Cookfair, D. L. – Rudick, R. A., et al.: Intramuscular interferon beta-1a for disease progression in exacerbating-remitting
multiple sclerosis. Ann Neurol, 1996, 39, s. 285–294.
9 PRISMS study group: Randomised double-blind placebo-controlled
study of interferon beta-1a in relapsing/remitting multiple sclerosis.
PRISMS (Prevention of Relapses and Disability by interferon β-1a in
Subcutaneously in Multiple Sclerosis) Study Group. Lancet, 1998, 352,
s. 1498–1504.
10Jacobs, L. D. – Beck, R. W. – Simon, J. H., et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in
multiple sclerosis. N Eng J Med, 2000, 343, s. 898–904.
11Comi, G. – Filippi, M. – Barkof, F., et al.: Effect of early treatment on
conversion to definite multiple sclerosis: A randomized study. Lancet,
2001, 357, s. 1576–1582.
12Horáková, D.: Léčba klinicky izolovaného syndromu a remitentní roztroušené sklerózy – aktuální doporučení zohledňující nové etiopatogenetické poznatky. Neurol pro praxi, 2010, 13, s. 8–11.
13Kappos, L. – Freedman, M. S. – Polman, C. H. – Edan, G. – Hartung,
H. P. – Miller, D. H. – Montalbán, X. – Barkhof, F. – Radu, E. W. – Metzig, C. – Bauer, L. – Lanius, V. – Sandbrink, R. – Pohl, C. – BENEFIT
Study Group: Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year
active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol, 2009, 8, s. 987–997.
14Souhrn údajů o přípravku, SUKL, Interferon beta-1a, http://www.ema.
europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf, vyhledáno dne 14. 12. 2012.
15Cohen, J. A. – Barkhof, M. – Comi, G. – Hartung, H. P. – Khatri, B. –
Montalban, X., et al.: TRANSFORMS Study Group. Oral fingolimod or
intramuscular interferon for relapsing multiple sclerosis. N Eng J Med,
2010, 362, s. 402–415.
16Panitch, H. – Goodin, D. S. – Francis, G. – Chang, P. – Coyle, P. K. –
O‘Connor, P., et al.: Randomized komparative study of interferon beta
1a treatment regiment in MS: the EVIDENCE trial. Neurology, 2002, 59,
s. 1496–1506.
Systémová léčba osteolýzy indukované nádorem
MUDr. Simona Paulíková | prof. MUDr. Jiří Petera Ph.D. | MUDr. Adam Paulík
LF UK a Klinika onkologie a radioterapie FN Hradec Králové
1 Coleman, R, E.: Metastatic bone disease: Clinical features, pathophysio­
logy and treatement strategie. Cancor Treat Rev, 2001, 27, s. 165–176.
2 Wardley, A. M.: Bone disease in cancer: a growing health problem.
In: Bone disease in cancer. Abstract book of the congress. Itálie, Benátky,
24.–25. 6. 2006.
3 Holubec, L. – Matějka, V. M.: Význam PET/CT pro diagnostiku a kontrolu léčby nemocných s kostními metastázami z pohledu klinické onkologie. Edukační sborník XXXV. Brněnských onkologických dní, 2011,
s. 263–264.
4 Kolář, J.: Metastázy do skeletu. Radiodiagnostika, 2005, svazek 51, č. 6.
ACTA MEDICINAE 2/2013 ALERGOLOGIE, PNEUMOLOGIE Kompletní literatura
5 Křístek, J.: Perkutánní cementoplastika osteolytických metastáz do
skeletu. Edukační sborník XXXV. Brněnských onkologických dní, 2011,
s. 265–266.
6 Hortobagyi, G. N.: Novel approaches to the management of bone
metastase. Semin Oncol, 2003, 30 (dopl. 16), s. 161–166.
7 Hortobagyi, G. N.: Treatement of brest cancor. N Engl J Med, 1998, 339,
s. 974–984.
8 Fleisch, H.: Bisphosphonates: A new vlase druha in disease of bone
and kalcium metabolism. In: Brunner, K. W. – Fleish, H. – Senn, H. J.,
eds.: Bisphosphonates and Tumor Osteolysis. Německo, Berlín, Springer-Verlag, 1989, s. 1–28.
9 Parker, C. – Heindrich, D. – O´Sulivan, L. M., et al.: Overall surfoval
benefit of radium-223 chloride (Alpharadin) in the treatement of patiens with symptomatic bone metastase on satration-resistantn prostate cancor: A phase III randomized trial (ALSYMPCA). ECCO-ESMO,
2011, abstrakt 1LBA.
10Barton, M. K.: Denosumab an option for patients with bone metastasis from breast cancer. CA Cancer J Clin, 2011, květen, s. 135–136.
Antitrombotická léčba – léčba apixabanem
MUDr. Hynek Poul Oddělení hematologie a transfuziologie Nemocnice Pelhřimov, p. o.
1 Ericsson, B. I. – Quinlan, D. J. – Weitz, J. I.: Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa
inhibitors in development. Clin Pharmacokinet, 2009, 48, s. 1–22.
2 Turpie, A. G. G.: Oral, direct Factor Xa inhibitors in development for
the prevention and treatment of thromboembolic diseases. Arterio­
scler Thromb Vasc Biol, 2007, 27, s. 1238–1247.
3 Ansell, J. J.: Factor Xa or thrombin: is factor Xa a better target? Thromb
Haemost, 2007, 5, s. 60–64.
4 Larsen, M. R., et al.: APROPOS=Apixaban PROphylaxis in Patients undergoing total knee replacement Surgery. J Thromb Haemost, 2007, 5,
s. 2368–2375.
5 SPC Eliquis.
6 Raskob, G. E. – Gallus, A. S. – Pineo, G. F. – Chen, D. – Ramirez, L. M. –
Wright, R. T. – Larsen, M. R.: Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from
the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br, 2012, 94,
s. 257–264.
7 Wang et al.: Prezentováno na WCCPT 2008. Poster T2TH071.
8 Barrett, Y. C. – Wang, Z. – Frost, C. – Shenker, A.: Clinical laboratory
measurement of direct factor Xa inhibitors: anti-Xa assay is preferable
to prothrombin time assay. Thromb Haemost, 2010, 104, s. 1263–1271.
9 Gogarten, W., et al.: Regional anaesthesia and antithrombotic agents:
recommendations of the European Society of Anaesthesiology. Eur J
Anaesthesiol, 2010, 27, s. 999–1015.
10Eikelboom, J. W. – O‘Donnell, M. – Yusuf, S. – Diaz, R. – Flaker, G. –
Hart, R. – Hohnloser, S. – Joyner, C. – Lawrence, J. – Pais, P. – Pogue,
J. – Synhorst, D. – Connolly, S. J.: Rationale and design of AVERROES:
apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J, 2010, 159, s. 348–353.
11Yates, S. W.: Apixaban for stroke prevention in atrial fibrillation: a review
of the clinical trial evidence. Hosp Pract (Minneap), 2011, 39, s. 7–16.
12Granger, C. B.: ARISTOTLE Committees and Investigators. Apixaban
versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011,
15, 365, s. 981–992.
13Wong, P. C. – Pinto, D. J. P. – Zhang, D.: Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb
Thrombolysis, 2011, 31, s. 478–492. Publikováno on-line 13. 2. 2011,
doi: 10.1007/s11239-011-0551-3.
Novinky ve fekální bakterioterapii
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha
1 Eiseman, B. – Silen, W. – Bascom, G. S. – Kauvar, A. J.: Fecal enema
as an adjunct in the treatment of pseudomembranous enterocolitis.
Surgery, 1958, 44, s. 854–859.
2 Kelly, C. P. – LaMont, J. T.: Clostridium difficile – more difficult than
ever. NEJM, 2008, 359, s. 1932–1940.
3 Gough, E. – Shaikh, H. – Magnes, A. R.: Systematic review of intestinal
microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clinical Infectious Diseases, 2011, 53, s. 994–1002.
4 Kelly, C. P.: Fecal microbiota transplantation – an old therapy comes of age. NEJM, 2013, publikováno před tiskem, doi: 10.1056/
NEJMe1214816.
5 van Nood, E. – Vrieze, A. – Nieuwdorp, M. – Fuentes, S. – Zoetendal,
E. G. – de Vos, W. M. – Visser, C. E. – Kuijper, E. J. – Bartelsman, J. F. W.
M. – Tijssen, J. G. P. – Speelman, P. – Dijkgraaf, M. G. W. – Keller, J. J.:
Duodenal infusion of donor feces for recurrent Clostridium difficile.
NEJM, 2013, publikováno před tiskem, doi: 10.1056/NEJMoa1205037.
6 Petrof, E. O. – Gloor, G. – Vanner, S. J. – Weese, S. J. – Carter, D. – Daig­
neault, M. C. – Brown, E. M. – Schroerter, K. – Allen-Vercoe, E.: Stool
substitute transplant therapy for the eradication of Clostridium difficile
infection: “RePOOPulating” the gut. Microbiome, 2013, 1, s. 3.
7 Tvede, M. – Rask-Madsen, J.: Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six pacients. Lancet, 1989, 1,
s. 1156–1160.
8 Upadhyay, V. – Poroyko, V. – Kim, T. – Devkota, S. – Fu, S. – Liu, D. –
Tumanov, A. V. – Koroleva, E. P. – Deng, L. – Nagler, C. – Chang, E. B. –
Tang, H. – Fu, Y-X.: Lymphotoxin regulates commensal responses to
enable diet-induced obesity. Nature Immunology, 2012, 13, s. 947–953.
9 Smith, M. I. – Yatsunenko, T. – Manary, M. J. – Trehan, I. – Mkakosya,
R. – Cheng, J. – Kau, A. L. – Rich, S. S. – Concannon, P. – Mychaleckyj, J. C. – Liu, J. – Houpt, E. – Li, J. V. – Holmes, E. – Nicholson, J. –
Knights, D. – Ursell, L. K. – Knight, R. – Gordon, J. I.: Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science, 2013,
339, s. 548–554.
10Quince, C. – Lundin, E. E. – Andreasson, A. N. – Greco, D. – Rafter, J. –
Talley, N. J. – Agreus, L. – Andersson, A. F. – Engstrand, L. – D‘Amato,
M.: The impact of Crohn‘s disease genes on healthy human gut microbiota: a pilot study. Gut, 2013, publikováno před tiskem, doi:10.1136/
gutjnl-2012-304214.
ACTA MEDICINAE 2/2013 ALERGOLOGIE, PNEUMOLOGIE Kompletní literatura